Study Provides Real-World Evidence for Inflammatory DED - Takeaways - MDSpire

Study Provides Real-World Evidence for Inflammatory DED

Carolina L. Mercado, MD, and colleagues presented data from the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry linked to pharmacy claims data sourced from the Komodo Health Research Dataset.

  • By

  • Julie Greenbaum, editor

  • Julie Greenbaum, editor

  • April 11, 2026

  • 4 min

Share

  • 1

    The study analyzed data from 143,005 patients diagnosed with dry eye disease who initiated lifitegrast therapy between 2017 and 2024.

  • 2

    The cohort was predominantly female (80%) with a mean age of 61 years, reflecting diverse geographic and insurance backgrounds.

  • 3

    Cataract was the most common ocular comorbidity, while hyperlipidemia and hypertension were the most prevalent nonocular comorbidities.

  • 4

    Only 10% of patients had previously used other therapies, indicating a large untreated population in the early stages of DED.

  • 5

    Diagnostic testing for dry eye was underutilized, with less than 4% diagnosed with evaporative dry eye based on tear breakup time.

Original Source(s)

Study Provides Real-World Evidence for Inflammatory DED

  • by Julie Greenbaum, editor, Julie Greenbaum, editor

  • April 11, 2026

Related Content

Comparative study of the therapeutic effects of different medications on DM-associated dry eye syndrome after vitrectomy

Integrated management of dry eye–depression comorbidity: mechanistic insights and temporal therapeutic strategies

The Importance of Treating OSD and Lid Margin Disease Preoperatively

Marjan Farid, MD, discusses her ASCRS Cornea Day presentation on preoperatively treating DED and OSD.

  • April 11, 2026

  • 4 min